Semaglutide News and Research

Latest Semaglutide News and Research

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

Study delves into the concept of 'food noise,' referring to persistent thoughts about eating, and assesses its impact on eating behaviors and obesity treatments. It explores how GLP-1RAs, a class of drugs used for weight management, might influence food cue reactivity, potentially offering new insights into obesity treatment and the psychological aspects of eating behaviors.

30 Nov 2023

The role of the brainstem in appetite suppression

The role of the brainstem in appetite suppression.

28 Nov 2023

New insights into the brain's control of eating speed

When you eagerly dig into a long-awaited dinner, signals from your stomach to your brain keep you from eating so much you'll regret it – or so it's been thought.

22 Nov 2023

Single injection of novel hydrogel could replace weekly diabetes injections

Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro, Trulicity, Victoza, and others to just once every four months.

22 Nov 2023

Eating more ultra-processed foods may increase risk of upper aerodigestive tract cancers

Eating more ultra-processed foods (UPFs) may be associated with a higher risk of developing cancers of upper aerodigestive tract (including the mouth, throat and oesophagus), according to a new study led by researchers from the University of Bristol and the International Agency for Research on Cancer (IARC).

22 Nov 2023

From hospital to hospitality: Spin doctors brand getting sick as an adventure. It’s not.

The last time I stepped on a plane for vacation, for fun, was more than three years ago. I haven't been able to visit California, whose coast I adore. Nor Rome, where my husband and I lived for some time.

22 Nov 2023

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

The study investigates the role of epigenetic changes in GLP1R gene polymorphisms on metabolically healthy obesity (MHO), revealing that apart from genetic variations, DNA methylation significantly influences the occurrence of MHO.

20 Nov 2023

Biden administration’s limit on drug industry middlemen backfires, pharmacists say

The Biden administration's first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry's price negotiators is backfiring, pharmacists say.

15 Nov 2023

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

Diabetes breakthrough: Scientists uncover novel route to stimulate beta cell growth

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes.

8 Nov 2023

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.

2 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

How does the Mediterranean diet impact insulin resistance and sensitivity in obese individuals?

Researchers evaluate the associations between adherence to the Mediterranean diet, insulin secretion, resistance, and sensitivity in obese individuals.

30 Oct 2023

KFF Health News' 'What the Health?': The new speaker’s (limited) record on health

After nearly a month of bickering, House Republicans finally elected a new speaker: Louisiana Republican Rep. Mike Johnson, a relative unknown to many.

26 Oct 2023

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

22 Oct 2023

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Researchers investigate if oat polar lipid compounds improve glucose tolerance, gut hormonal responses, and triglyceridemia.

20 Oct 2023

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.

17 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

Semaglutide News and Research

Latest Semaglutide News and Research

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

The role of the brainstem in appetite suppression

New insights into the brain's control of eating speed

Single injection of novel hydrogel could replace weekly diabetes injections

Eating more ultra-processed foods may increase risk of upper aerodigestive tract cancers

From hospital to hospitality: Spin doctors brand getting sick as an adventure. It’s not.

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

Biden administration’s limit on drug industry middlemen backfires, pharmacists say

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Diabetes breakthrough: Scientists uncover novel route to stimulate beta cell growth

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Citrus compounds show zesty promise in type 2 diabetes management

How does the Mediterranean diet impact insulin resistance and sensitivity in obese individuals?

KFF Health News' 'What the Health?': The new speaker’s (limited) record on health

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Semaglutide News and Research

Latest Semaglutide News and Research

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Newsletters you may be interested in